Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 4 study being conducted at the Ohio State University Department of Neurology
Multiple Sclerosis Research Program. The purpose of the study is to administer a single shot
of intrathecal (injection into the space surrounding the spinal cord via a lumbar puncture or
spinal tap) ziconotide as a test dose to patients who have chronic painful myelopathy (pain
from spinal cord damage) or painful peripheral neuropathy (pain from nerve damage) that has
not responded to other pain medicines.